Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Phase I study of IOA-244 in follicular lymphoma

Carmelo Carlo-Stella, MD, PhD, Humanitas Clinical and Research Center, Rozzano, Italy, comments on the preliminary findings of a Phase I study evaluating IOA-244, a PI3Kδ inhibitor, in patients with follicular lymphoma (FL) (NCT04328844). Prof. Carlo-Stella explains that this combination appears to be well-tolerated. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.